HC Wainwright Has Negative Estimate for SENS Q3 Earnings

Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) – Investment analysts at HC Wainwright reduced their Q3 2026 earnings estimates for shares of Senseonics Holdings, Inc. Common Stock in a research report issued to clients and investors on Friday, August 7th. HC Wainwright analyst S. Lee now expects that the company will post earnings of ($0.58) per share for the quarter, down from their prior estimate of ($0.54). HC Wainwright currently has a “Buy” rating and a $14.00 target price on the stock. The consensus estimate for Senseonics Holdings, Inc. Common Stock’s current full-year earnings is ($2.38) per share. HC Wainwright also issued estimates for Senseonics Holdings, Inc. Common Stock’s Q4 2026 earnings at ($0.52) EPS, FY2026 earnings at ($2.41) EPS, Q1 2027 earnings at ($0.58) EPS, Q2 2027 earnings at ($0.55) EPS, Q3 2027 earnings at ($0.51) EPS, Q4 2027 earnings at ($0.40) EPS, FY2027 earnings at ($2.05) EPS, FY2028 earnings at ($1.60) EPS, FY2029 earnings at ($1.15) EPS and FY2030 earnings at ($0.60) EPS.

Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.08). Senseonics Holdings, Inc. Common Stock had a negative return on equity of 165.80% and a negative net margin of 225.09%.The company had revenue of $14.48 million for the quarter.

SENS has been the topic of several other research reports. Mizuho cut their price objective on Senseonics Holdings, Inc. Common Stock from $20.00 to $18.00 and set an “outperform” rating on the stock in a report on Wednesday, July 15th. Stifel Nicolaus cut their price target on shares of Senseonics Holdings, Inc. Common Stock from $9.00 to $8.00 and set a “hold” rating on the stock in a research note on Monday, May 11th. Weiss Ratings raised shares of Senseonics Holdings, Inc. Common Stock from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 28th. Finally, Wall Street Zen raised shares of Senseonics Holdings, Inc. Common Stock from a “strong sell” rating to a “sell” rating in a research note on Saturday. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $17.20.

Senseonics Holdings, Inc. Common Stock Stock Up 7.4%

NASDAQ:SENS opened at $7.54 on Tuesday. Senseonics Holdings, Inc. Common Stock has a 52 week low of $4.79 and a 52 week high of $11.58. The company has a quick ratio of 6.40, a current ratio of 6.74 and a debt-to-equity ratio of 0.62. The stock’s fifty day moving average price is $5.87. The firm has a market capitalization of $315.17 million, a PE ratio of -3.38 and a beta of 1.01.

Institutional Investors Weigh In On Senseonics Holdings, Inc. Common Stock

A number of hedge funds and other institutional investors have recently modified their holdings of SENS. J.Safra Asset Management Corp purchased a new stake in shares of Senseonics Holdings, Inc. Common Stock during the 2nd quarter worth $636,000. Kestra Advisory Services LLC purchased a new stake in Senseonics Holdings, Inc. Common Stock during the 1st quarter worth about $68,000. GSK plc acquired a new position in shares of Senseonics Holdings, Inc. Common Stock during the 4th quarter worth about $60,000. State of Wyoming acquired a new stake in shares of Senseonics Holdings, Inc. Common Stock during the 2nd quarter worth about $67,000. Finally, Cetera Investment Advisers purchased a new stake in Senseonics Holdings, Inc. Common Stock during the first quarter worth approximately $85,000. 12.36% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Senseonics Holdings, Inc. Common Stock

Here are the key news stories impacting Senseonics Holdings, Inc. Common Stock this week:

• Positive Sentiment: HC Wainwright continues to rate Senseonics “Buy” and retained its $14.00 target price, signaling confidence in the company’s long-term prospects despite ongoing losses.
• Neutral Sentiment: The analyst expects losses to narrow over time, forecasting EPS of ($2.05) in FY2027, ($1.60) in FY2028, ($1.15) in FY2029 and ($0.60) in FY2030. However, the company is still expected to remain unprofitable through FY2030.
• Negative Sentiment: HC Wainwright reduced its FY2026 EPS forecast to ($2.41) from ($2.23), compared with the current consensus estimate of ($2.38). It also lowered FY2027 EPS to ($2.05) from ($1.97), FY2028 to ($1.60) from ($1.57), FY2029 to ($1.15) from ($1.13), and FY2030 to ($0.60) from ($0.59).
• Negative Sentiment: Near-term quarterly forecasts were also cut: Q3 2026 EPS to ($0.58) from ($0.54), and Q4 2026 EPS to ($0.52) from ($0.48). These revisions point to deeper expected losses and may weigh on sentiment.

Senseonics Holdings, Inc. Common Stock Company Profile

Senseonics Holdings, Inc develops and commercializes long-term implantable continuous glucose monitoring (CGM) systems for people with diabetes. The company’s primary product family is the Eversense system, which combines a small subcutaneously implanted sensor, a removable external transmitter, and companion smartphone applications to provide continuous glucose readings and alerts. Senseonics positions its technology as an alternative to wearable patch-style CGMs by offering multi-month sensor longevity and on-body vibration alerts delivered through the transmitter.

Senseonics supports clinical and commercial activities that include research and development, regulatory engagement, manufacturing and distribution, and training for healthcare providers who perform sensor insertion and removal.